Marked hypertriglyceridemia in a woman receiving metoprolol succinate

Yeunjung Kim , Michael Miller
Journal of Clinical Lipidology 8 ( 6) 640 -643

1
2014
Poly is more effective than monounsaturated fat for dietary management in the metabolic syndrome: The muffin study

Michael Miller , John D. Sorkin , Laura Mastella , Aimee Sutherland
Journal of Clinical Lipidology 10 ( 4) 996 -1003

22
2016
COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS

William S. Weintraub , Deepak Bhatt , Zugui Zhang , Cheng Zhang
Journal of the American College of Cardiology 75 ( 11) 1914

4
2020
Multiple splice defects in ABCA1 cause low HDL-C in a family with hypoalphalipoproteinemia and premature coronary disease.

Jeffrey Rhyne , Myrna M Mantaring , David F Gardner , Michael Miller
BMC Medical Genetics 10 ( 1) 1 -11

56
2009
Niacin as a Component of Combination Therapy for Dyslipidemia

Michael Miller
Mayo Clinic Proceedings 78 ( 6) 735 -742

52
2003
Genetics of HDL regulation in humans

Michael Miller , Jeffrey Rhyne , Steven Hamlette , Josh Birnbaum
Current Opinion in Lipidology 14 ( 3) 273 -279

83
2003
Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment.

Farhan Majeed , Michael Miller
Current Opinion in Endocrinology, Diabetes and Obesity 15 ( 2) 175 -181

14
2008
81
2007
TCT CONNECT-3 Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI

Benjamin Peterson , Deepak Bhatt , Philippe Steg , Michael Miller
Journal of the American College of Cardiology 76 ( 17)

2020
Characterization of Myocardial Injury in Patients With COVID-19.

Gennaro Giustino , Lori B Croft , Giulio G Stefanini , Renato Bragato
Journal of the American College of Cardiology 76 ( 18) 2043 -2055

305
2020
Translating standards into practice: one semantic web API for gene expression

Helena F. Deus , Philippe Rocca Serra , M. Scott Marshall , Jun Zhao
semantic web applications and tools for life sciences 6 -7

3
2011
Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.

Najdat Bazarbashi , Michael Miller
Expert Review of Cardiovascular Therapy 18 ( 4) 175 -180

1
2020
Intensive Care Services in the Veterans Health Administration

Peter Almenoff , Anne Sales , Sharon Rounds , Michael Miller
Chest 132 ( 5) 1455 -1462

23
2007
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.

Deepak L. Bhatt Ph. Gabriel Steg Eliot A. Brinton Terry A. Jacobson Michael Miller Jean‐Claude Tardif Steven B. Ketchum Ralph T. Doyl ,
Circulation 141 ( 5) 367 -375

44
2020
Response by Bhatt et al to Letter Regarding Article, "REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States".

Deepak L. Bhatt , Rebecca A. Juliano , Steven B. Ketchum , Michael Miller
Circulation 141 ( 21)

2
2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.

Benjamin E Peterson , Deepak L Bhatt , Ph Gabriel Steg , Michael Miller
Circulation 143 ( 1) 33 -44

2
2021
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

Allen J. Taylor , Todd C. Villines , Eric J. Stanek , Patrick J. Devine
The New England Journal of Medicine 361 ( 22) 2113 -2122

595
2009
Cardiovascular efficacy and safety of bococizumab in high-risk patients

Paul M Ridker , James Revkin , Pierre Amarenco , Robert Brunell
The New England Journal of Medicine 376 ( 16) 1527 -1539

582
2017
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Deepak L Bhatt , P Gabriel Steg , Michael Miller , Eliot A Brinton
The New England Journal of Medicine 380 ( 1) 11 -22

2,172
2019